Omicron News and Research

RSS

Do the symptom profiles among children with SARS-CoV-2 infection differ by variant type?

Researchers performed a comparative analysis of symptoms related to SARS-CoV-2 variants in children.

14 Mar 2023

Bispecific antibody shows improved efficacy against SARS-CoV-2 variants

Researchers from The University of Texas MD Anderson Cancer Center have developed fully human bispecific antibodies, as revealed in a recent study. These antibodies can bind to two distinct epitopes of the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and have demonstrated the ability to neutralize various strains of the virus, including the Omicron variant.

14 Mar 2023

Kinetics of successive SARS-CoV-2 infections

Researchers compare viral kinetics of successive SARS-CoV-2 infections.

13 Mar 2023

How does temperature affect host responses to SARS-CoV-2 and IAV infection in human nasal epithelial cells?

A new preprint examines the response to these pathogens in the nose, which is the primary portal of entry for both.

13 Mar 2023

SARS-CoV-2 replication persists for weeks in lungs after symptom onset in severe COVID-19

Researchers observe persistent SARS-CoV-2 replication in severe COVID-19 patient lungs.

13 Mar 2023

How effective are monovalent mRNA COVID-19 vaccine booster doses against Omicron-associated severe outcomes among adults?

Researchers from Canada investigated the efficacy of booster doses of the monovalent mRNA COVID-19 vaccine in preventing hospitalization and death during the dominance of the SARS-CoV-2 Omicron variant.

10 Mar 2023

New class of oral drugs can inhibit a diverse range of pathogenic SARS-CoV-2 strains

The constant evolution of new COVID-19 variants makes it critical for clinicians to have multiple therapies in their arsenal for treating drug-resistant infections.

9 Mar 2023

Evaluating SARS-CoV-2 bivalent booster vaccine against severe COVID-19 outcomes

In a recent study posted to the medRxiv* preprint server, researchers assessed the effectiveness of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) bivalent booster vaccine against severe SARS-CoV-2 infection outcomes.

9 Mar 2023

COVID-19 patients at increased risk of developing gastrointestinal disorders

People who have had COVID-19 are at increased risk of developing gastrointestinal (GI) disorders within a year after infection compared with people who haven't been infected, according to an analysis of federal health data by researchers at Washington University School of Medicine in St. Louis and the Veterans Affairs St. Louis Health Care system.

8 Mar 2023

Symptomatic COVID-19 is associated with deficits in task-related cognitive function and psychiatric symptoms

Researchers conducted a prospective population survey, functional brain imaging, and a cognitive task performance test to determine whether a history of symptomatic coronavirus disease 2019 (COVID-19) was associated with psychiatric and neurocognitive symptoms.

7 Mar 2023

Effectiveness of monovalent COVID-19 mRNA booster vaccination vs. two-dose primary series during Omicron variant circulation

Researchers estimated the immune protection conferred by monovalent-type COVID-19 mRNA booster doses vs. two-dose prime vaccination series during SARS-CoV-2 Omicron variant predominance in community settings.

7 Mar 2023

Antibody levels from prime COVID-19 mRNA vaccine influences the efficacy of booster doses

Researchers evaluate the response of pre-existing immunity to booster doses of mRNA COVID-19 vaccines.

6 Mar 2023

Cirrhosis associated with lower immune responses to COVID-19 vaccines in patients with chronic liver disease

The overall responsiveness of patients with chronic liver disease (CLD) to COVID-19 vaccines has been shown to be decreased in patients with cirrhosis.

2 Mar 2023

SARS-CoV-2 BA.1 and BA.2 breakthrough infections likely protect against BA.4 infection

Omicron BTIs induce durable neutralizing immune responses by recalling cross-reactive and vaccine-induced memory B lymphocytes.

1 Mar 2023

Covid-19 vaccination can curb the effect of long COVID on patients' social, professional, and family lives

Vaccination against SARS-CoV-2, the virus responsible for COVID-19, may lessen the severity and duration of 'long COVID' in those with persistent symptoms after infection, suggests a study that closely imitates a randomized clinical trial, and published in the open access journal, BMJ Medicine.

1 Mar 2023

The effects of Omicron emergence on seroprevalence and hybrid immunity in the Finnish adult population

Researchers evaluated SARS-CoV-2 seroprevalence and population-level humoral immunity among Finnish individuals between April 2020 and December 2022.

28 Feb 2023

Study finds celebrity tweets likely shaped US negative public opinion of COVID-19 pandemic

Researchers evaluated the influence of celebrities on public attitudes toward the COVID-19 pandemic.

28 Feb 2023

High-dose ivermectin does not reduce COVID-19 symptom duration among mild-to-moderate outpatients

Researchers evaluate the efficacy of ivermectin in a maximum dosage of 600 μg/kg/day over six days in treating early mild-to-moderate COVID-19.

27 Feb 2023

Study shows COVID-19 rates were likely forty-times higher than CDC estimates during BA.4/BA.5 dominant period in the U.S.

Researchers evaluate the prevalence of SARS-CoV-2 infections and the incidence of long COVID during BA.4/BA.5 dominant period.

27 Feb 2023

Is the advantage conferred by the heterologous regimen conserved after a booster dose of mRNA-based COVID-19 vaccine?

Researchers compared the efficacy of a third COVID-19 vaccine dose and that of homologous and heterologous regimens.

23 Feb 2023

Omicron News and Research

Do the symptom profiles among children with SARS-CoV-2 infection differ by variant type?

Bispecific antibody shows improved efficacy against SARS-CoV-2 variants

Kinetics of successive SARS-CoV-2 infections

How does temperature affect host responses to SARS-CoV-2 and IAV infection in human nasal epithelial cells?

SARS-CoV-2 replication persists for weeks in lungs after symptom onset in severe COVID-19

How effective are monovalent mRNA COVID-19 vaccine booster doses against Omicron-associated severe outcomes among adults?

New class of oral drugs can inhibit a diverse range of pathogenic SARS-CoV-2 strains

Evaluating SARS-CoV-2 bivalent booster vaccine against severe COVID-19 outcomes

COVID-19 patients at increased risk of developing gastrointestinal disorders

Symptomatic COVID-19 is associated with deficits in task-related cognitive function and psychiatric symptoms

Effectiveness of monovalent COVID-19 mRNA booster vaccination vs. two-dose primary series during Omicron variant circulation

Antibody levels from prime COVID-19 mRNA vaccine influences the efficacy of booster doses

Cirrhosis associated with lower immune responses to COVID-19 vaccines in patients with chronic liver disease

SARS-CoV-2 BA.1 and BA.2 breakthrough infections likely protect against BA.4 infection

Covid-19 vaccination can curb the effect of long COVID on patients' social, professional, and family lives

The effects of Omicron emergence on seroprevalence and hybrid immunity in the Finnish adult population

Study finds celebrity tweets likely shaped US negative public opinion of COVID-19 pandemic

High-dose ivermectin does not reduce COVID-19 symptom duration among mild-to-moderate outpatients

Study shows COVID-19 rates were likely forty-times higher than CDC estimates during BA.4/BA.5 dominant period in the U.S.

Is the advantage conferred by the heterologous regimen conserved after a booster dose of mRNA-based COVID-19 vaccine?

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News